Literature DB >> 12399463

Betaglycan expression is transcriptionally up-regulated during skeletal muscle differentiation. Cloning of murine betaglycan gene promoter and its modulation by MyoD, retinoic acid, and transforming growth factor-beta.

Fernando Lopez-Casillas1, Cecilia Riquelme, Yoshiaki Perez-Kato, M Veronica Ponce-Castaneda, Nelson Osses, Jose Esparza-Lopez, Gerardo Gonzalez-Nunez, Claudio Cabello-Verrugio, Valentin Mendoza, Victor Troncoso, Enrique Brandan.   

Abstract

Betaglycan is a membrane-anchored proteoglycan co-receptor that binds transforming growth factor beta (TGF-beta) via its core protein and basic fibroblast growth factor through its glycosaminoglycan chains. In this study we evaluated the expression of betaglycan during the C(2)C(12) skeletal muscle differentiation. Betaglycan expression, as determined by Northern and Western blot, was up-regulated during the conversion of myoblasts to myotubes. The mouse betaglycan gene promoter was cloned, and its sequence showed putative binding sites for SP1, Smad3, Smad4, muscle regulatory factor elements such as MyoD and MEF2, and retinoic acid receptor. Transcriptional activity of the mouse betaglycan promoter reporter was also up-regulated in differentiating C(2)C(12) cells. We found that MyoD, but not myogenin, stimulated this transcriptional activity even in the presence of high serum. Betaglycan promoter activity was increased by RA and inhibited by the three isoforms of TGF-beta. On the other hand, basic fibroblast growth factor, BMP-2, and hepatocyte growth factor/scatter factor, which are inhibitors of myogenesis, had little effect. In myotubes, up-regulated betaglycan was also detectable by TGF-beta affinity labeling and immunofluorescence microscopy studies. The latter indicated that betaglycan was localized both on the cell surface and in the ECM. Forced expression of betaglycan in C(2)C(12) myoblasts increases their responsiveness to TGF-beta2, suggesting that it performs a TGF-beta presentation function in this cell lineage. These results indicate that betaglycan expression is up-regulated during myogenesis and that MyoD and RA modulate its expression by a mechanism that is independent of myogenin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399463     DOI: 10.1074/jbc.M208520200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Phenotype specific association of the TGFBR3 locus with nonsyndromic cryptorchidism.

Authors:  Julia S Barthold; Yanping Wang; Thomas F Kolon; Claude Kollin; Agneta Nordenskjöld; Alicia Olivant Fisher; T Ernesto Figueroa; Ahmad H BaniHani; Jennifer A Hagerty; Ricardo Gonzalez; Paul H Noh; Rosetta M Chiavacci; Kisha R Harden; Debra J Abrams; Cecilia E Kim; Abigail B Mateson; Alan K Robbins; Jin Li; Robert E Akins; Hakon Hakonarson; Marcella Devoto
Journal:  J Urol       Date:  2014-10-25       Impact factor: 7.450

2.  Retinoic acid enhances lactoferrin-induced IgA responses by increasing betaglycan expression.

Authors:  Jeong-Min Lee; Young-Saeng Jang; Bo-Ra Jin; Sun-Jin Kim; Hyeon-Jin Kim; Bo-Eun Kwon; Hyun-Jeong Ko; Sung-Il Yoon; Geun-Shik Lee; Woan-Sub Kim; Goo-Young Seo; Pyeung-Hyeun Kim
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

3.  MyoD control of SKIP expression during pig skeletal muscle development.

Authors:  Q Xiong; J Chai; P P Zhang; J Wu; S W Jiang; R Zheng; C Y Deng
Journal:  Mol Biol Rep       Date:  2010-03-25       Impact factor: 2.316

4.  Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Authors:  S J Cooper; H Zou; S N Legrand; L A Marlow; C A von Roemeling; D C Radisky; K J Wu; N Hempel; V Margulis; H W Tun; G C Blobe; C G Wood; J A Copland
Journal:  Oncogene       Date:  2010-03-08       Impact factor: 9.867

5.  Blockade of Bradykinin receptors worsens the dystrophic phenotype of mdx mice: differential effects for B1 and B2 receptors.

Authors:  María José Acuña; Daniela Salas; Adriana Córdova-Casanova; Meilyn Cruz-Soca; Carlos Céspedes; Carlos P Vio; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2017-12-17       Impact factor: 5.782

6.  The type III TGF-β receptor betaglycan transmembrane-cytoplasmic domain fragment is stable after ectodomain cleavage and is a substrate of the intramembrane protease γ-secretase.

Authors:  Cheyne R Blair; Jacqueline B Stone; Rebecca G Wells
Journal:  Biochim Biophys Acta       Date:  2010-12-15

7.  Decorin interacts with connective tissue growth factor (CTGF)/CCN2 by LRR12 inhibiting its biological activity.

Authors:  Cecilia Vial; Jaime Gutiérrez; Cristian Santander; Daniel Cabrera; Enrique Brandan
Journal:  J Biol Chem       Date:  2011-03-23       Impact factor: 5.157

8.  Dual role of SnoN in mammalian tumorigenesis.

Authors:  Qingwei Zhu; Ariel R Krakowski; Elizabeth E Dunham; Long Wang; Abhik Bandyopadhyay; Rebecca Berdeaux; G Steven Martin; LuZhe Sun; Kunxin Luo
Journal:  Mol Cell Biol       Date:  2006-10-30       Impact factor: 4.272

9.  Expression of the type III TGF-beta receptor is negatively regulated by TGF-beta.

Authors:  Nadine Hempel; Tam How; Simon J Cooper; Tyler R Green; Mei Dong; John A Copland; Christopher G Wood; Gerard C Blobe
Journal:  Carcinogenesis       Date:  2008-02-24       Impact factor: 4.944

10.  Constitutively activated dystrophic muscle fibroblasts show a paradoxical response to TGF-beta and CTGF/CCN2.

Authors:  Valeria Mezzano; Daniel Cabrera; Cecilia Vial; Enrique Brandan
Journal:  J Cell Commun Signal       Date:  2008-04-15       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.